Daily administration of low molecular weight heparin increases Hepatocyte Growth Factor serum levels in gynaecological patients: pharmacokinetic parameters and clinical implications
Anna Surbone(A. O. Ordine Mauriziano di Torino), Paolo Zola(A. O. Ordine Mauriziano di Torino), Annamaria Ferrero, Annalisa Luchin(A. O. Ordine Mauriziano di Torino), Cosimo Martino(Candiolo Cancer Institute), Maria Flavia Di Renzo(Cancer Genetics (United States)), Roberto Passera(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Cristiana Marchese(A. O. Ordine Mauriziano di Torino), Luca Fuso(A. O. Ordine Mauriziano di Torino)
Cited by 3
Related Papers
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
|Annals of Oncology|2019|1.2k
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
|The Lancet Oncology|2016|1k
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study
|Modern Pathology|2015|317